Jena M. Krueger

Dr. Jena M. Krueger

Pediatric Neurology
35 Michigan Street Northeast, Suite 3003, 
Grand Rapids, MI 
On Staff At
16 Years of Experience
35 Michigan Street Northeast, Suite 3003, 
Grand Rapids, MI 
OverviewInsuranceLocationsClinical Research

Overview

Jena Krueger is a Pediatric Neurologist in Grand Rapids, Michigan. Dr. Krueger has been practicing medicine for over 16 years and is rated as an Experienced provider by MediFind in the treatment of Porencephaly. Her top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 1, and Spinal Muscular Atrophy Type 2.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Michigan State University College Of Human Medicine, 2010
Residency
Northwestern Memorial Hospital
Specialties
Pediatric Neurology
Licenses
Neurology with Special Qualifications in Neurology in MI
Board Certifications
American Board Of Psychiatry And Neurology
American Board Of Psychiatry And Neurology
Fellowships
Northwestern Memorial Hospital
Hospital Affiliations
Corewell Health Grand Rapids Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Corewell Health Pediatric Neurology - 35 Michigan St NE
35 Michigan Street Northeast, Suite 3003, Grand Rapids, MI 49503
Other Locations
Corewell Health Neurosciences Grand Rapids
1234 Napier Avenue, Saint Joseph, MI 49085
Corewell Health Pediatric Neurosurgery - Royalton
3950 Hollywood Road, Suite 240, Saint Joseph, MI 49085
Corewell Health Pediatric Neurology - Munson Ave, Traverse City
880 Munson Avenue, Suite H, Traverse City, MI 49686

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
View 2 Less Clinical Trials

17 Total Publications

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.
Journal: The Lancet. Neurology
Published: March 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krueger's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile